story of the week
ESMO 2021: Pembrolizumab Shows Benefit for Resected, High-Risk Stage II Melanoma in KEYNOTE-716
Results were consistent across patient subtypes
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.